These findings clarify how myeloid cell heterogeneity shapes ICB outcomes in HCC and highlight the VEGFA–HBEGF axis as a central conduit for angiogenesis-driven immunosuppression. This evidence concerns the gene VEGFA and hepatocellular carcinoma.